Clinical trials have already proven that anti-PD-1/PD-L1 therapy provides antitumor activity and has an acceptable safety profile when used to treat HNSCC patients, although several studies have reported that HNSCC sufferers respond to PD-1/PD-L1 therapy regardless of their HPV status11. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.